Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Rajca S, et al. Among authors: flamant m. Inflamm Bowel Dis. 2014 Jun;20(6):978-86. doi: 10.1097/MIB.0000000000000036. Inflamm Bowel Dis. 2014. PMID: 24788220 Clinical Trial.
Ovarian reserve in young women of reproductive age with Crohn's disease.
Fréour T, Miossec C, Bach-Ngohou K, Dejoie T, Flamant M, Maillard O, Denis MG, Barriere P, Bruley des Varannes S, Bourreille A, Masson D. Fréour T, et al. Among authors: flamant m. Inflamm Bowel Dis. 2012 Aug;18(8):1515-22. doi: 10.1002/ibd.21872. Epub 2011 Sep 20. Inflamm Bowel Dis. 2012. PMID: 21936034
Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E, Mary JY, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Porcher R, Paintaud G, Piver E, Colombel JF, Lemann M; Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives. Louis E, et al. Among authors: flamant m. Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31. doi: 10.1053/j.gastro.2011.09.034. Epub 2011 Sep 22. Gastroenterology. 2012. PMID: 21945953
Serum calprotectin as a biomarker for Crohn's disease.
Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E; GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives). Meuwis MA, et al. J Crohns Colitis. 2013 Dec;7(12):e678-83. doi: 10.1016/j.crohns.2013.06.008. Epub 2013 Jul 9. J Crohns Colitis. 2013. PMID: 23845231 Clinical Trial.
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Abitbol Y, Laharie D, Cosnes J, Allez M, Nancey S, Amiot A, Aubourg A, Fumery M, Altwegg R, Michetti P, Chanteloup E, Seksik P, Baudry C, Flamant M, Bouguen G, Stefanescu C, Bourrier A, Bommelaer G, Dib N, Bigard MA, Viennot S, Hébuterne X, Gornet JM, Marteau P, Bouhnik Y, Abitbol V, Nahon S; GETAID. Abitbol Y, et al. Among authors: flamant m. J Crohns Colitis. 2016 Oct;10(10):1179-85. doi: 10.1093/ecco-jcc/jjw129. Epub 2016 Jul 11. J Crohns Colitis. 2016. PMID: 27402916
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease.
Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lʼhopital F, Luneau F, Michalet V, Genès J, Achim A, Cruzille E, Bommelaer G, Laharie D, Peyrin-Biroulet L, Pereira B, Nachury M, Bouguen G; ACCEPT study group. Buisson A, et al. Among authors: flamant m. Inflamm Bowel Dis. 2017 Aug;23(8):1425-1433. doi: 10.1097/MIB.0000000000001140. Inflamm Bowel Dis. 2017. PMID: 28570431
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G. Rayer C, et al. Among authors: flamant m. BMC Gastroenterol. 2022 Dec 1;22(1):498. doi: 10.1186/s12876-022-02583-5. BMC Gastroenterol. 2022. PMID: 36457080 Free PMC article.
204 results